Drug intelligence / Profile preview

BIO105

Development stage: Preclinical
Lead developer: Boostimmune
Modality: Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BIO105 (also known as BIO-105) is an early-stage immune-stimulating antibody conjugate (ISAC) being developed by Boostimmune. It is designed to target and modulate immunosuppressive myeloid cells, specifically myeloid-derived suppressor cells (MDSCs), within the tumor microenvironment to activate anti-tumor immune responses. BIO105 is currently in the discovery/preclinical stage of development for the treatment of neoplasms (cancer).

Beyond the preview

Go deeper on BIO105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIO105.

Explore the full profile